Jordyn Sava | Authors

Jordyn Sava is an assistant editor for Targeted Oncology.


Ultra-Low Dose of Radiation Shows Promise in Orbital Indolent B-Cell Lymphomas

November 28, 2022

In an interview with Targeted Oncology, Chelsea C. Pinnix discussed the results of a phase 2 study and how these promising results will shift the treatment paradigm of patients with orbital indolent B-cell lymphoma.

Pralsetinib Shows Positive Phase 1/2 Results in RET Fusion+ NSCLC

November 26, 2022

Updated analysis from the phase 1/2 ARROW study evaluating pralsetinib in patients with RET fusion-positive non–small cell lung cancer showed the agent to be well tolerated and to elicit clinical activity at a dose of 400 mg daily.

Understanding Recent Developments in Mantle Cell Lymphoma

November 23, 2022

In an interview with Targeted Oncology, Jia Ruan, MD, PhD, discussed the updates in the mantle cell lymphoma space, including understanding molecular pathogenesis and risk stratification for this patient population.